ASH 2018 | Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Thanks for your feedback, this will help us improve our content for you!
Venetoclax, a BCL-2 inhibitor, has shown promising efficacy in Waldenström macroglobulinemia (WM) patients. Here, Jorge Castillo, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the results of the Phase II study (NCT02677324) evaluating the safety and efficacy of venetoclax monotherapy in previously treated WM patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Castillo reveals that venetoclax is well tolerated, producing high levels of response in patients with symptomatic, previously treated WM, including those exposed to BTK inhibitors.
Get great new content delivered to your inboxSign up